The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

GSK’s blood cancer drug Blenrep has been reapproved by the EU medicines regulator after it was removed from sale in 2023 because a trial failed to show it was superior to other treatments.

GSK’s share price has fallen a lot in 10 months, which means it could be a huge bargain. I ran the key numbers and examined ...

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.